Related Experiment Video
Updated: Oct 10, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus
K A Abraham1, M A Little, A M Dorman
1Department of Nephrology, Beaumont Hospital, Dublin 9, Ireland.
Abstract:
Hemolytic-uremic syndrome (HUS) is a well-recognized complication of cyclosporine (CyA) therapy. Transplant recipients with this complication are frequently switched to tacrolimus, although this drug has also been implicated. We report a case of a renal transplant recipient who developed severe graft dysfunction due to biopsy-proven HUS after receiving CyA. Renal function and hemolytic parameters improved with discontinuation of the drug, but they deteriorated again after commencement of tacrolimus 15 days later. A second transplant biopsy demonstrated fresh lesions diagnostic of HUS. Hemolytic parameters resolved with discontinuation of tacrolimus. This is the first report of metachronous HUS being caused in a renal transplant by both CyA and tacrolimus. We therefore believe that caution should be exercised when using tacrolimus as rescue therapy in patients with CyA-induced HUS.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Drug Toxicity: Allergic Reactions
Hypersensitivity Reactions: Cytolytic Reactions
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Nephrotic Syndrome II : Assessment and Medical Management
